This story originally ran on Nov. 4.
Myriad Genetics has eight protein-based tests progressing toward commercialization, company officials said this week on a conference call discussing the firm's earnings for the quarter ended Sept. 30.
With the deal, Myriad will acquire RBM's biomarker discovery platform as well as its pipeline of proprietary protein biomarker-based diagnostics, including two tests that a Myriad official said were "relatively close to commercial launch."
WSU and the Michigan Technology and Research Institute are seeking funding to form a company to shepherd to clinical trials WSU's first candidate, a triple uptake inhibitor for treating depression. They eventually hope to attract a pharma partner for further development.
The toolkit is the first product released under the Consensus Measures for Phenotypes and eXposures initiative, which is a three-year project aimed at developing a set of standard measures across 20 research categories related to health and common diseases.
The approximately $17 million acquisition, announced last week, will have "no impact" on Clinical Data's focus as a pharmacogenomics company, according to CEO Drew Fromkin.
